Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Sarcoma 1Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 535Uterine Cervical Neoplasms 249Fallopian Tube Neoplasms 239Endometrial Neoplasms 142Carcinoma, Ovarian Epithelial 135Breast Neoplasms 101Neoplasms 74Carcinoma, Non-Small-Cell Lung 70Colorectal Neoplasms 53Uterine Cervical Dysplasia 49Papillomavirus Infections 49Neoplasm Metastasis 48Pancreatic Neoplasms 46Melanoma 44Uterine Neoplasms 43Prostatic Neoplasms 41Urinary Bladder Neoplasms 40Lung Neoplasms 40Stomach Neoplasms 38Peritoneal Neoplasms 37Recurrence 36Carcinoma, Renal Cell 35Triple Negative Breast Neoplasms 33Head and Neck Neoplasms 32Esophageal Neoplasms 31Small Cell Lung Carcinoma 30Sarcoma 28Vulvar Neoplasms 26Vaginal Neoplasms 24Testicular Neoplasms 22

Interventions

human papillomavirus vaccine, L1 type 16, 18 3halofantrine 1Papillomavirus Vaccines 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Virus Diseases × Gynecologic × Clear all
NCT05453006 2025-07-10

Isbaar

University of Minnesota

Phase NA Completed
3,367 enrolled 8 charts
Gynecologic

Uterine Cervical Diseases, Uterine Cervical Neoplasms, DNA Virus Infections, Infections, Papilloma, Tumor Virus Infections, Uterine Diseases, Virus Diseases, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

GlaxoSmithKline

Phase 3 Completed
1,106 enrolled 27 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00492544 2018-09-04

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

GlaxoSmithKline

Phase 3 Completed
100 enrolled 9 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

GlaxoSmithKline

Phase 1 Completed
961 enrolled 43 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡